A venture firm with offices in Canada and the USA is investing from its second fund. The firm makes equity investments in early-stage life science companies based in Canada and the USA, and prefers to lead or co-lead investments. Initial investments will typically be of about $5 million CAD, with capital reserved for potential follow-on investments of up to $15 million CAD total per opportunity. The firm is likely to make 12-15 investments over the fund’s lifetime, with a focus on Canada; the firm also invests in the USA.
The firm will make most of its allocations in the therapeutics sector, with the remainder invested in diagnostics, medical devices, and/or tools or healthcare IT. The firm prefers to invest in early-stage opportunities; in the therapeutics sector, investments may be made in companies with a lead product 12-18 months prior to IND. The fund is generally agnostic in terms of technological field and indication area.
The firm only invests in those therapeutic companies that have identified a lead product candidate.
If you are interested in more information about this investor and other investors tracked by LSN, please email firstname.lastname@example.org